 NSCLC patients have to be stable PR or SD after first-line chemotherapy in order to be enrolled. A total of 12 to 24 patients are planned. Patients will remain on the dose throughout the trial. It is intended to administer at least 4 cycles 21 d each, or until progression or 2nd line therapy becomes necessary. 